{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:57:07Z","timestamp":1772632627417,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Crohn\u2019s disease (CD) is a disabling inflammatory disorder with highly variable response to biologic therapies. Despite the availability of multiple biologic agents, a significant proportion of patients experience primary non-response, while others initially respond but subsequently develop secondary loss of response, leading to sequential treatment failures and increased healthcare burden. The disease course and response to treatment are remarkably heterogeneous among patients, and a better understanding of the personalised pathways affected is required. Identifying early biomarkers of treatment efficacy is crucial for improving patient outcomes and reducing unnecessary healthcare costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we comprehensively analysed T cell subpopulations in blood and lamina propria, together with serum cytokine profiles, in CD patients receiving the IL-12\/IL-23 inhibitor ustekinumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The most remarkable findings were observed in peripheral blood. At week 24, good responders showed decreased Th1, increased Th2, and reduced IL-17A serum levels compared with non-responders. Importantly, elevated IL-12\/IL-23 serum levels at week 8 associated with favourable clinical and endoscopic outcomes, suggesting effective pathway blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings support the measurement of serum IL-12\/IL-23 at week 8 as a simple, early predictor of ustekinumab response in CD, potentially guiding personalised treatment strategies and ultimately long-term response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1753914","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:03:14Z","timestamp":1772607794000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["T cell and cytokine signatures as early predictors of response to IL-12\/IL-23 inhibition in Crohn\u2019s disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Eduardo","family":"Mart\u00edn Arranz","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Group of Gastrointestinal Immune-Mediated Diseases IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Garc\u00eda-Ramirez","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Group of Gastrointestinal Immune-Mediated Diseases IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Van Den Rym","sequence":"additional","affiliation":[{"name":"Laboratory of Immunogenetics of Human Diseases, IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Innate Immunity Group, IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Interdepartmental Group of Immunodeficiencies","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Suarez","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Group of Gastrointestinal Immune-Mediated Diseases IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Garc\u00eda-Sol\u00eds","sequence":"additional","affiliation":[{"name":"Laboratory of Immunogenetics of Human Diseases, IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Innate Immunity Group, IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Interdepartmental Group of Immunodeficiencies","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nestor","family":"D\u00edaz-Iglesias","sequence":"additional","affiliation":[{"name":"Laboratory of Immunogenetics of Human Diseases, IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Innate Immunity Group, IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Interdepartmental Group of Immunodeficiencies","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"L\u00f3pez-Lera","sequence":"additional","affiliation":[{"name":"IdiPAZ Institute for Health Research, La Paz University Hospital, CIBERER U-754","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Corvillo","sequence":"additional","affiliation":[{"name":"IdiPAZ Institute for Health Research, La Paz University Hospital, CIBERER U-754","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Rueda Garc\u00eda","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Group of Gastrointestinal Immune-Mediated Diseases IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Blanco-San Miguel","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Group of Gastrointestinal Immune-Mediated Diseases IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"S\u00e1nchez Azofra","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Group of Gastrointestinal Immune-Mediated Diseases IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Poza Cord\u00f3n","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Group of Gastrointestinal Immune-Mediated Diseases IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Itan","sequence":"additional","affiliation":[{"name":"The Charles Bronfman Institute for Personalized Medicine and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai","place":["New York, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"L\u00f3pez-Collazo","sequence":"additional","affiliation":[{"name":"Group of Gastrointestinal Immune-Mediated Diseases IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Innate Immunity Group, IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca","family":"P\u00e9rez de Diego","sequence":"additional","affiliation":[{"name":"Laboratory of Immunogenetics of Human Diseases, IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Innate Immunity Group, IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Interdepartmental Group of Immunodeficiencies","place":["Madrid, Spain"]},{"name":"CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Mart\u00edn-Arranz","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"Group of Gastrointestinal Immune-Mediated Diseases IdiPAZ Institute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]},{"name":"School of Medicine, Universidad Aut\u00f3noma de Madrid","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.4161\/self.1.4.13560","article-title":"Immunopathogenesis of inflammatory bowel disease","volume":"1","author":"Matricon","year":"2010","journal-title":"Self Nonself"},{"key":"B2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"M","year":"2012","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.10.008","article-title":"Immune aspects\u00a0of the pathogenesis of inflammatory bowel disease","volume":"137","author":"Hisamatsu","year":"2012","journal-title":"Pharmacol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.02.011","article-title":"Development of the human gastrointestinal microbiota and insights from high-throughput sequencing","volume":"140","author":"Dominguez-Bello","year":"2011","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.02.046","article-title":"Recent insights into the genetics of inflammatory bowel disease","volume":"140","author":"Cho","year":"2011","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1097\/MOG.0b013e328360bd12","article-title":"Epigenetics: the fine-tuner in inflammatory bowel disease","volume":"29","author":"Stylianou","year":"2013","journal-title":"Curr Opin Gastroenterol"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.4161\/epi.29446","article-title":"DNA methylation-associated colonic mucosal immune and defense responses in treatment-naive pediatric ulcerative colitis","volume":"9","author":"Harris","year":"2014","journal-title":"Epigenetics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000063","article-title":"Linking immunity, epigenetics, and cancer in inflammatory bowel disease","volume":"20","author":"D\u00e4britz","year":"2014","journal-title":"Inflammation Bowel Dis"},{"key":"B10","article-title":"DNA methylation changes in inflammatory bowel disease","volume":"27","author":"Karatzas","year":"2014","journal-title":"Ann Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8813558","DOI":"10.1155\/2020\/8813558","article-title":"The function and role of the th17\/treg cell balance in inflammatory bowel disease","volume":"2020","author":"Yan","year":"2020","journal-title":"J Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00617","article-title":"TCR signaling in T cell memory","volume":"6","author":"Daniels","year":"2015","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cgh.2017.11.050","article-title":"Association of vedolizumab level, anti-drug antibodies, and \u03b14\u03b27 occupancy with response in patients with inflammatory bowel diseases","volume":"16","author":"Ungar","year":"2018","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15484","article-title":"Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases","volume":"50","author":"Singh","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14548","article-title":"Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study","volume":"47","author":"Yacoub","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/14712598.2019.1561850","article-title":"Anti-interleukin-12 and anti-interleukin-23 agents in Crohn\u2019s disease","volume":"19","author":"Macaluso","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz186","article-title":"Efficacy of JAK inhibitors in crohn\u2019s disease","volume":"14","author":"Rogler","year":"2020","journal-title":"J Crohns Colitis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jaci.2012.11.050","article-title":"Deficiency of caspase recruitment domain family, member 11 (CARD11), causes profound combined immunodeficiency in human subjects","volume":"131","author":"Stepensky","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000740","article-title":"New targets in inflammatory bowel disease therapy: 2021","volume":"37","author":"Cohen","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/apt.16785","article-title":"Review article: emerging drug therapies in inflammatory bowel disease","volume":"55","author":"Grossberg","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1724-23","article-title":"Ustekinumab decreases circulating th17 cells in ulcerative colitis","volume":"63","author":"Imazu","year":"2024","journal-title":"Intern Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3748\/wjg.14.390","article-title":"Immunopathogenesis of inflammatory bowel disease","volume":"14","author":"Shih","year":"2008","journal-title":"World J Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02148","article-title":"A double edged sword role of interleukin-22 in wound healing and tissue regeneration","volume":"11","author":"Arshad","year":"2020","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet (Lond Engl)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1753914\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:03:17Z","timestamp":1772607797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1753914\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1753914"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1753914","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1753914"}}